CMMB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

CMMB ▲ +7.06% at T+5d

NEUTRAL call ✓ call won +7.06% · α vs SPY +7.78% · entry $1.70 → $1.82

Next anchor: T+20d in 2d

Last close $1.81 (close Jun 8) · +6.47% from $1.70 entry

Entry anchored
May 13, 03:56 PM ET
via Databento tick

T+1d

-2.35%

call -2.35% · α -1.13%

$1.66

settled 26d ago

T+5d

+7.06%

call +7.06% · α +7.78%

$1.82

settled 20d ago

T+20d

—

call — · α —

—

in 2d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The company highlighted new biomarker data from its Phase 2 SPRING trial suggesting nebokitug may benefit PSC patients with coexisting IBD, and continues pursuing partnership discussions. Cash runway extends through Q1 2027, but at a $13M market cap the stock remains a binary-option on partnership or Phase 3 outcomes.

Actionable Insight

The stock is a binary catalyst play on partnership news or Phase 3 trial updates. With $8M cash lasting ~3 more quarters and no revenue, the company must secure a partnership or financing by mid-2027. Monitor EASL 2026 presentations (May 30) for any partnership announcement or data that could trigger a re-rating.

Key Facts

Q1 2026 net loss of $1.8M vs $3.3M in Q1 2025; R&D expenses fell to $0.9M from $2.5M as Phase 2 SPRING trial wound down
Cash, equivalents and short-term deposits of $8.0M as of March 31, 2026, down from $10.4M at year-end 2025; runway through Q1 2027
New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 suggest nebokitug modulates gut-liver inflammatory pathways relevant to PSC-IBD comorbidity
Company continues advancing multiple partnering options for nebokitug; no definitive partnership announced
FDA alignment on Phase 3 registration trial design for PSC previously achieved; nebokitug has FDA/EMA Orphan Drug and FDA Fast Track designations for PSC

Financial Impact

Cash burn of ~$2.4M in Q1 2026; cash runway of ~$8M expected to fund operations through Q1 2027

cashnet lossR&D expenses

Risk Factors

Cash runway only through Q1 2027; dilutive financing likely if partnership does not materialize
No approved products or revenue; full reliance on nebokitug clinical and regulatory success
Phase 3 PSC trial carries inherent clinical and regulatory risk; biomarker data may not translate to clinical endpoints
Low liquidity ($13M market cap) amplifies price volatility on any news

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

88% bullish (8 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3294834

5 reports for CMMB

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CMMB — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	6-K NEUTRAL ★ 2/10	$1.72 $1.80	▲ +4.65%	▲ +4.25%	$1.81 (+5.23%)
May 14, 2026 26d ago	6-K NEUTRAL ★ 5/10	$1.70 $1.66	▼ −2.35%	▼ −1.13%	$1.81 (+6.47%)
May 14, 2026 26d ago	Press Release NEUTRAL ★ 4/10	$1.70 $1.66	▼ −2.35%	▼ −1.13%	$1.81 (+6.47%)
May 6, 2026 4w ago	6-K NEUTRAL ★ 2/10	$1.74 $1.77	▲ +1.72%	▲ +0.89%	$1.81 (+4.02%)
Mar 19, 2026 11w ago	Press Release BULLISH ★ 8/10	$1.93 $1.78	▼ −7.77%	▼ −6.03%	$1.81 (−6.22%)

US Market Status

Market Closed — Opens in 7h 21m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access